Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,591 recruiting studies in this area right now.
By phase
- Not applicable9,784
- Phase 24,449
- Phase 12,735
- Phase 1/Phase 21,686
- Phase 31,394
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,225
- Cancer661
- Prostate Cancer653
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer289
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)286
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas638
- Arizona512
- Florida448
- Alabama420
- New York408
- Massachusetts343
- Maryland330
- New Jersey269
- Pennsylvania242
Recruiting studies20,591 total
- NCT04313140Recruiting
MRI virtual biopsy to predict glioma grade
This study uses special MRI images to estimate the “grade” of a suspected brain tumor (glioma) without taking a tissue sample first. If it works well, it may help doctors better plan care based on imaging.
PoitiersAges 18 years+ - NCT07104240Recruiting
Improving HPV vaccination for preteens ages 9-12
This study tests a program designed to help primary care practices increase HPV vaccination rates among adolescents aged 9 to 12 who haven't yet been vaccinated. It aims to find out if providing practices with resources and support can lead to more kids getting the HPV vaccine.
Atlanta, GeorgiaAges 9 years+ - NCT04365036RecruitingPhase 3
Check if PD-1 plus chemo-radiation helps early nasal lymphoma
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Guangzhou, GuangdongAges 18–75 - NCT05848609Recruiting
Quality of life study for older adults having robotic colon surgery
This study looks at how older people feel and function after robotic surgery for colorectal cancer. It may help doctors understand what to expect and how to better support quality of life during recovery.
BrusselsAges 70 years+ - NCT03962920Recruiting
Personalized care for urologic cancer based on gut and urine bacteria
This study looks at how your body’s bacteria (microbiome in and around the urinary/genital area) may help guide personalized treatment for localized urologic cancers. The goal is to see whether tailoring treatment to your bacteria could improve outcomes.
RoskildeAges 40–70 - NCT04432714RecruitingPhase 1/Phase 2
Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Nanjing, JiangsuAges 18–60 - NCT05589701Recruiting
Compare two radiation plans for painful spinal cancer spread
This study compares two different radiation approaches—SBRT and CRT—for people with painful cancer that has spread to the spine. It may help determine which plan controls pain and tumor growth while limiting side effects to nearby organs.
Toronto, OntarioAges 18–100 - NCT04282083Recruiting
Registry for adults with confirmed digestive neuroendocrine tumors
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
Rozzano, MilanAges 18 years+ - NCT04070040RecruitingPhase 2
Camrelizumab for returning brain lymphoma after prior treatment
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
BeijingAges 18 years+ - NCT04216121Recruiting
Testing a focused radiation approach for limited cancer spread
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
LeuvenAges 18 years+ - NCT03837782Enrolling by invitation
Surgery outcomes for early to mid-stage colon cancer
This study looks at how well surgery works for people with colorectal cancer that has not spread to distant organs. It mainly includes patients who can have the tumor completely removed and accurately staged using lymph node samples.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT05512754RecruitingPhase 4
Test whether anti-inflammatory medicine helps when PSA is high
This trial studies whether taking anti-inflammatory medicine (ibuprofen or similar “NSAID” drugs) can improve what doctors learn in people whose PSA blood test is higher than expected and who need more prostate testing. It may help reduce unnecessary procedures or improve next-step decisions, but only if you meet safety and eligibility rules.
Chicago, IllinoisAges 18–80 - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT03966612Recruiting
Monitoring people with MEN1 and related hormone gland tumors
This study follows people who have Multiple Endocrine Neoplasia type 1 (MEN1), a genetic condition that can cause tumors in hormone glands. It aims to monitor symptoms and lesions over time to better understand how the condition progresses and how to manage it.
DijonAges Any age - NCT04602377RecruitingPhase 2
Pembrolizumab with standard chemo for ovarian small cell cancer
This Phase 2 trial tests whether adding pembrolizumab (an immune medicine) to standard chemotherapy can improve outcomes for people with small cell cancer of the ovary that has not been treated before. It may help your immune system recognize and attack the cancer while you receive chemotherapy.
AngersAges 12 years+ - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT04150640RecruitingPhase 2
Chemo drug combination for advanced stomach or esophagus cancer
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Madison, WisconsinAges 18 years+ - NCT04330456Recruiting
Radiation plus surgery for first soft tissue sarcoma
This trial studies a treatment plan for newly diagnosed soft tissue sarcoma that combines precisely targeted radiation before surgery and conformal radiation after surgery. It may help by improving tumor control while allowing the surgeon to remove the tumor safely.
Saint PetersburgAges 18–75 - NCT04560036Recruiting
FAZA PET/MR scan for stomach and esophagus cancer
This study uses a special PET/MR scan (FAZA with imaging) to better understand stomach and esophagus cancer. You may be able to join if you have eligible cancer and can safely complete the scan.
Toronto, OntarioAges 18 years+ - NCT04438889Recruiting
Join the Austrian myeloid patient registry
This is a registry study that collects information from people with myeloid blood diseases. It helps researchers better understand these conditions and support future research.
FeldkirchAges 18 years+ - NCT03897374Recruiting
Hereditary cancer testing for older adults with family history
This trial looks at using genetic (DNA) cancer testing decisions that are based on “medical necessity” and what your doctor thinks is right for your care. It may help patients and families better understand inherited cancer risk and prevention options.
Prosper, TexasAges 65 years+ - NCT05599412Recruiting
Tracking safety of Lorviqua in ALK-positive lung cancer
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
SeoulAges 18 years+ - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,591 recruiting oncology studies from the U.S. registry right now, out of 31,235 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.